King's College London

Research portal

PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease

Research output: Contribution to journalArticle

Standard

PR3-ANCA : A promising biomarker for ulcerative colitis with extensive disease. / Mahler, Michael; Bogdanos, Dimitrios P.; Pavlidis, Polychronis; Fritzler, Marvin J.; Csernok, Elena; Damoiseaux, Jan; Bentow, Chelsea; Shums, Zakera; Forbes, Alastair; Norman, Gary L.

In: Clinica Chimica Acta, Vol. 424, 23.09.2013, p. 267-273.

Research output: Contribution to journalArticle

Harvard

Mahler, M, Bogdanos, DP, Pavlidis, P, Fritzler, MJ, Csernok, E, Damoiseaux, J, Bentow, C, Shums, Z, Forbes, A & Norman, GL 2013, 'PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease', Clinica Chimica Acta, vol. 424, pp. 267-273. https://doi.org/10.1016/j.cca.2013.06.005

APA

Mahler, M., Bogdanos, D. P., Pavlidis, P., Fritzler, M. J., Csernok, E., Damoiseaux, J., ... Norman, G. L. (2013). PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease. Clinica Chimica Acta, 424, 267-273. https://doi.org/10.1016/j.cca.2013.06.005

Vancouver

Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Damoiseaux J et al. PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease. Clinica Chimica Acta. 2013 Sep 23;424:267-273. https://doi.org/10.1016/j.cca.2013.06.005

Author

Mahler, Michael ; Bogdanos, Dimitrios P. ; Pavlidis, Polychronis ; Fritzler, Marvin J. ; Csernok, Elena ; Damoiseaux, Jan ; Bentow, Chelsea ; Shums, Zakera ; Forbes, Alastair ; Norman, Gary L. / PR3-ANCA : A promising biomarker for ulcerative colitis with extensive disease. In: Clinica Chimica Acta. 2013 ; Vol. 424. pp. 267-273.

Bibtex Download

@article{dea2a21de65c458fbb9e8e273f7ce2c4,
title = "PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease",
abstract = "Background: We determined if PR3-ANCA is a biomarker that differentiates ulcerative colitis (UC) from Crohn's disease (CrD). Methods: A total of 946 sera were tested, including 86 granulomatosis with polyangiitis (GPA) and 491 inflammatory bowel disease (IBD) patients (283 UC and 208 CrD), 264 pathological controls (various diseases) and 105 healthy individuals. All samples were tested for PR3-ANCA by ELISA (QUANTA Flash Lite{\circledR}, INOVA Diagnostics) and chemiluminescent immunoassays (CIA QUANTA Flash PR3). Conventional anti-neutrophil cytoplasmic antibody (ANCA) indirect immunofluorescence assays (IIF) was performed with NOVA Lite™ (INOVA Diagnostics). Results: PR3-ANCA by CIA were detected in 31.1{\%} UC vs. 1.9{\%} CrD sera (p=. 2.2E. -. 16), and by ELISA in 6{\%} UC and 0{\%} CrD (p=. 0.0003). In GPA patients, PR3-ANCA were detected in 75.6{\%} by CIA and 61.6{\%} by ELISA (p",
keywords = "Autoimmune disease, Crohn's disease, Inflammatory bowel disease, PR3-ANCA, Ulcerative colitis",
author = "Michael Mahler and Bogdanos, {Dimitrios P.} and Polychronis Pavlidis and Fritzler, {Marvin J.} and Elena Csernok and Jan Damoiseaux and Chelsea Bentow and Zakera Shums and Alastair Forbes and Norman, {Gary L.}",
year = "2013",
month = "9",
day = "23",
doi = "10.1016/j.cca.2013.06.005",
language = "English",
volume = "424",
pages = "267--273",
journal = "Clinica Chimica Acta",
issn = "0009-8981",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - PR3-ANCA

T2 - A promising biomarker for ulcerative colitis with extensive disease

AU - Mahler, Michael

AU - Bogdanos, Dimitrios P.

AU - Pavlidis, Polychronis

AU - Fritzler, Marvin J.

AU - Csernok, Elena

AU - Damoiseaux, Jan

AU - Bentow, Chelsea

AU - Shums, Zakera

AU - Forbes, Alastair

AU - Norman, Gary L.

PY - 2013/9/23

Y1 - 2013/9/23

N2 - Background: We determined if PR3-ANCA is a biomarker that differentiates ulcerative colitis (UC) from Crohn's disease (CrD). Methods: A total of 946 sera were tested, including 86 granulomatosis with polyangiitis (GPA) and 491 inflammatory bowel disease (IBD) patients (283 UC and 208 CrD), 264 pathological controls (various diseases) and 105 healthy individuals. All samples were tested for PR3-ANCA by ELISA (QUANTA Flash Lite®, INOVA Diagnostics) and chemiluminescent immunoassays (CIA QUANTA Flash PR3). Conventional anti-neutrophil cytoplasmic antibody (ANCA) indirect immunofluorescence assays (IIF) was performed with NOVA Lite™ (INOVA Diagnostics). Results: PR3-ANCA by CIA were detected in 31.1% UC vs. 1.9% CrD sera (p=. 2.2E. -. 16), and by ELISA in 6% UC and 0% CrD (p=. 0.0003). In GPA patients, PR3-ANCA were detected in 75.6% by CIA and 61.6% by ELISA (p

AB - Background: We determined if PR3-ANCA is a biomarker that differentiates ulcerative colitis (UC) from Crohn's disease (CrD). Methods: A total of 946 sera were tested, including 86 granulomatosis with polyangiitis (GPA) and 491 inflammatory bowel disease (IBD) patients (283 UC and 208 CrD), 264 pathological controls (various diseases) and 105 healthy individuals. All samples were tested for PR3-ANCA by ELISA (QUANTA Flash Lite®, INOVA Diagnostics) and chemiluminescent immunoassays (CIA QUANTA Flash PR3). Conventional anti-neutrophil cytoplasmic antibody (ANCA) indirect immunofluorescence assays (IIF) was performed with NOVA Lite™ (INOVA Diagnostics). Results: PR3-ANCA by CIA were detected in 31.1% UC vs. 1.9% CrD sera (p=. 2.2E. -. 16), and by ELISA in 6% UC and 0% CrD (p=. 0.0003). In GPA patients, PR3-ANCA were detected in 75.6% by CIA and 61.6% by ELISA (p

KW - Autoimmune disease

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - PR3-ANCA

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84880409853&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2013.06.005

DO - 10.1016/j.cca.2013.06.005

M3 - Article

C2 - 23806819

AN - SCOPUS:84880409853

VL - 424

SP - 267

EP - 273

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454